Search results
Results from the WOW.Com Content Network
Amisulpride is approved and used at low doses in the treatment of dysthymia and major depressive disorder. [10] [20] [11] [21] [22] [23] Whereas typical doses used in schizophrenia block postsynaptic dopamine D 2-like receptors and reduce dopaminergic neurotransmission, low doses of amisulpride preferentially block presynaptic dopamine D 2 and D 3 autoreceptors and thereby disinhibit dopamine ...
Zoetis markets cefpodoxime proxetil under the trade name Simplicef for veterinary use, and Finecure in India markets the drug as Cefpo. [3] [4] Vantin (by Pfizer) [5] in suspension or tablet form. Toraxim (by Delta Pharma Ltd., Bangladesh) Trucef (by Renata Limited, Bangladesh) Tricef (by Alkaloid Skopje, North Macedonia) Orelox (by Sanofi ...
A combination drug (or fixed-dose combination; FDC) is a product that contains more than one active ingredient (e.g., one tablet, one capsule, or one syrup with multiple drugs). In naturopathy , dosages can take the form of decoctions and herbal teas , in addition to the more conventional methods mentioned above.
Sulpiride, sold under the brand name Dogmatil among others, is an atypical antipsychotic (although some texts have referred to it as a typical antipsychotic) [10] medication of the benzamide class which is used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and is sometimes used in low dosage to treat anxiety and mild depression.
The United States Pharmacopeia (USP) is a pharmacopeia (compendium of drug information) for the United States published annually by the over 200-year old United States Pharmacopeial Convention (usually also called the USP), a nonprofit organization that owns the trademark and also owns the copyright on the pharmacopeia itself.
But nonprofessional users could benefit from reliable health information in a layperson-accessible format. [6] [7] [8] The National Library of Medicine introduced MedlinePlus in October 1998, to provide a non-commercial online service similar, for example, to the commercial WebMD. In 2010 another NCBI service, PubMed Health, complemented ...
Modified-release dosage is a mechanism that (in contrast to immediate-release dosage) delivers a drug with a delay after its administration (delayed-release dosage) or for a prolonged period of time (extended-release [ER, XR, XL] dosage) or to a specific target in the body (targeted-release dosage).
GLY-200 is an experimental drug that acts as a "polymeric mucin binding duodenal exclusion therapy"; it is developed by Glyscend Therapeutics for type 2 diabetes and obesity. It is intended to reversibly mimic the effects of gastric bypass without the need for surgery.